Abstract

Surface-associated proteins from Mycobacterium bovis BCG Moreau RDJ are important components of the live Brazilian vaccine against tuberculosis. They are important targets during initial BCG vaccine stimulation and modulation of the host's immune response, especially in the bacterial-host interaction. These proteins might also be involved in cellular communication, chemical response to the environment, pathogenesis processes through mobility, colonization, and adherence to the host cell, therefore performing multiple functions. In this study, the proteomic profile of the surface-associated proteins from M. bovis BCG Moreau was compared to the BCG Pasteur reference strain. The methodology used was 2DE gel electrophoresis combined with mass spectrometry techniques (MALDI-TOF/TOF), leading to the identification of 115 proteins. Of these, 24 proteins showed differential expression between the two BCG strains. Furthermore, 27 proteins previously described as displaying moonlighting function were identified, 8 of these proteins showed variation in abundance comparing BCG Moreau to Pasteur and 2 of them presented two different domain hits. Moonlighting proteins are multifunctional proteins in which two or more biological functions are fulfilled by a single polypeptide chain. Therefore, the identification of such proteins with moonlighting predicted functions can contribute to a better understanding of the molecular mechanisms unleashed by live BCG Moreau RDJ vaccine components.

Highlights

  • Tuberculosis (TB) is one of the 10 major causes of death worldwide

  • The regions of difference RD2 and RD14 are present in Bacillus Calmette-Guérin (BCG) Moreau, whereas RD16 is absent, when compared to BCG Pasteur [5]

  • The first goal of this study was to perform a proteomic analysis of surface-associated proteins of M. bovis BCG Moreau through 2DE gel electrophoresis and MALDI-TOF-TOF and compare it to M. bovis BCG Pasteur

Read more

Summary

Introduction

Tuberculosis (TB) is one of the 10 major causes of death worldwide. According to the World Health Organization (WHO), TB killed 1.7 million people in 2016 with 10.4 million new cases estimated worldwide ratifying the need for more effective treatment and prevention [1]. Because of in vitro evolution, slightly different BCG substrains emerged from the parental BCG, such as those with deletions and duplications of genomic regions and/or single nucleotide polymorphism (SNPs) well documented through analysis and genome sequencing [3,4,5,6,7,8,9]. These genetic differences among the various BCG strains in use worldwide partially explain the variable efficacy in protection against pulmonary TB in adults [2]. These particularities justify more detailed proteomic studies in order to elucidate which proteins are effectively expressed by these bacteria

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call